The second clinical scenario involves a 67-year-old patient with HER2-positive metastatic breast cancer receiving T-DXd (presumably with pertuzumab) for 11 months with ongoing partial response. The patient reports fatigue, intermittent nausea, and mild cough while expressing concerns about long-term treatment sustainability.
Dr. Rao immediately focuses on the mild cough as a potential ILD warning sign requiring urgent evaluation. Her protocol involves immediate oxygen saturation assessment and same-day high-resolution chest CT scheduling, emphasizing the critical nature of respiratory symptoms in T-DXd-treated patients.
Multidisciplinary coordination becomes essential for distinguishing ILD from other causes, involving pulmonology and infectious disease consultation. Seasonal respiratory viruses can complicate assessment, requiring comprehensive evaluation including respiratory pathogen testing alongside imaging studies.
Communication with radiologists about specific ILD screening needs ensures appropriate interpretation of imaging findings. The differential diagnosis requires systematic approach to avoid missing grade 1 ILD while avoiding unnecessary treatment interruptions for alternative diagnoses.
Dr. Kruse emphasizes palliative care consultation value for complex symptom management, particularly for fatigue assessment requiring evaluation of multiple contributing factors beyond cancer and treatment effects. Untreated sleep apnea, mood disorders, and thyroid dysfunction frequently contribute to fatigue burden.
Fatigue evaluation requires comprehensive internal medicine approach within oncology visits, though time constraints make this challenging. External perspectives from palliative care or other specialists provide valuable second opinions when oncologists develop assessment blind spots.
Polypharmacy reduction becomes important over time as patients accumulate medications for anxiety, sleep, and mood management that may need reassessment as clinical situations evolve. The 11-month treatment duration allows for medication review and optimization.
The combination of fatigue and cough raises particular concern for insidious ILD progression, requiring immediate evaluation rather than symptomatic management alone.
Both panelists emphasize the importance of maintaining open communication about symptom burden while ensuring appropriate safety evaluations for concerning symptoms like respiratory changes in T-DXd-treated patients.
